This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The 5 Dumbest Things on Wall Street This Week: Nov. 1

Stocks in this article: TEVA MCD JCP GS SHLD

1. Tough Times at Teva

Somebody better slip the folks over at Teva Pharmaceuticals (TEVA) a chill pill before things really get out of hand.

The world's largest generic drugmaker saw its stock get shellacked Wednesday after it revealed that its CEO Jeremy Levin was leaving and CFO Eyal Desheh was taking his spot on an interim basis. Teva shares were halted in Tel Aviv following the announcement and finished 8% lower in Nasdaq trading. Levin, who took Teva's top-spot in May 2012, denied an Israeli media report earlier in the week that Levin was clashing with the company's board of directors over Teva's strategy.

There you have it. Sometimes you should believe what you read in the papers.

And if you don't want to believe the media, then perhaps give Wall Street's scribes a perusal.

BMO Capital said it has less confidence in Teva following the CEO scuffle. BMO's analyst criticized the company's governance and said the last time Teva searched for a CEO its R&D and earnings suffered. Elsewhere, Piper Jaffray said the positive outlook from Teva on its CEO resignation call "does not square with the realities" of its underlying business.

Teva's CEO skirmish also couldn't have come at a worse time for the company. Teva announced it cutting 5,000 jobs earlier this month, or 10% of its workforce, as part of Levin's cost-cutting plan as it prepares for stiffer competition to its multiple sclerosis drug Copaxone. The board, the Israeli government and labor unions clashed with Levin over his handling of the layoffs, which some say led to his abrupt departure. On Thursday, Teva was back in the spotlight, reporting flat earnings that beat analysts' estimates by a cent.

"It just got to the point where the slight differences couldn't really be resolved. We thought it was better to part ways," said Teva board Chairman Dr. Phillip Frost on Wednesday's conference call.

We appreciate your honesty Dr. Frost. Chill pill, yes. Truth serum, no.

-- Written by Gregg Greenberg in New York

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
5 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs